Episode 324 - Dr. Anath Shalev - Founder and CSO - TIXiMED

In this episode of the Diabetes Innovators Series, Rob interviews Dr. Anath Shalev discussing the recent advancements in TIXiMed's TIX100, an oral therapy for type 1 diabetes. The conversation covers the successful completion of a phase one study, the implications of the results, and the potential impact of TIX100 on diabetes management. Dr. Shalev emphasizes the importance of addressing beta cell dysfunction and the exciting metabolic signals observed during the study. The discussion also touches on the future directions for TIX100 and its role in improving the lives of diabetes patients. Chapters Chapters 00:00 Introduction to TixiMed and TIX100 01:16 Phase One Study Results and Implications 05:22 Metabolic Signals and Future Studies 08:11 The Role of TIX100 in Diabetes Management 09:47 Future Directions and Patient Impact Resources: TIXiMED Dr. Anath Shalev

There are no comments yet.

Please log in to write the first comment.